Blood Clots in Antiphospholipid Syndrome

Table of Contents
View All
Table of Contents

Antiphospholipid syndrome (APS) is an autoimmune disease (when the body's immune system malfunctions and attacks healthy tissue) characterized by an increased risk of blood clots and pregnancy complications.

APS can occur in healthy individuals or people with an underlying autoimmune disorder like systemic lupus erythematosus (SLE), also known as lupus.

An illustration with symptoms and complications of antiphospholipid syndrome

Illustration by Zoe Hansen for Verywell Health

To be diagnosed, a person must have APS antibodies (immune system proteins) in addition to related symptoms like a history of blood clots and/or recurrent miscarriages.

This article reviews what it means to have antiphospholipid syndrome, its symptoms and complications, and how it's treated. Lifestyle habits to help prevent blood clots will also be discussed.

Antiphospholipid Syndrome: Why Does Clotting Happen?

Recurrent blood clots in arteries, veins, or small blood vessels are a cornerstone of antiphospholipid syndrome.

These blood clots are caused by antiphospholipid antibodies, proteins that target, attack, and damage phospholipids within blood vessels. Phospholipids are fatty molecules normally found in cell membranes, including cells that line blood vessels.

The antiphospholipid antibodies found in APS are:

The exact manner in which these antibodies lead to blood clot formation remains unknown. In fact, not everyone with these antibodies develops blood clots or has pregnancy complications.

Experts suspect a complex combination of genetic and environmental factors is involved. Specifically, genetically susceptible individuals with APS antibodies may develop blood clots when exposed to a trigger like trauma, surgery, or infection. Other factors, like vitamin D deficiency, could also play a role.

Secondary APS

APS is classified as either "primary" or "secondary." Primary APS occurs independently, whereas secondary APS occurs with another autoimmune condition, usually lupus.

The link between APS and lupus is strong. Approximately 50% of people with APS eventually develop SLE.

While not a complete list, other autoimmune diseases associated with secondary APS include;

Symptoms and Complications of Antiphospholipid Syndrome

The two hallmark features of antiphospholipid syndrome are blood clots and pregnancy-related problems.

Blood Clots

In antiphospholipid syndrome, blood clots can form in any blood vessel, including the arteries (blood vessels that take oxygen-rich blood away from the heart) and veins (blood vessels that take oxygen-poor blood to the heart).

Blood clots usually only develop at one site, although they can continue to form if not treated. A rare exception is catastrophic APS, in which multiple blood clots form in a short time frame.

The symptoms of APS are caused by the blockage of blood flow, which can impair organ function. They can be mild or severe, depending on the location and extent of the blood clot.

Types of blood clots seen in APS and their associated symptoms include:

  • Deep vein thrombosis (DVT) is a blood clot in a large deep vein, usually within the legs. Symptoms include pain, redness, swelling, and warmth of the leg.
  • A pulmonary embolus is a blood clot in the main artery of the lungs. Symptoms can include trouble breathing, chest pain, and a rapid heartbeat.
  • A transient ischemic attack (TIA), or an ischemic stroke, occurs when blood flow in an artery supplying the brain is blocked. Symptoms may include numbness, weakness, vision changes, or difficulty speaking.
  • Livedo reticularis is a blotchy, reddish-blue to purple rash caused by blood clots in the small vessels of the skin.
  • Renal vein thrombosis is when a blood clot forms in the blood vessel connecting the kidney to the heart, possibly causing kidney dysfunction.

Other health problems potentially seen in individuals with APS include:

  • Thrombocytopenia is low levels of platelets (blood cells involved in normal blood clotting), possibly leading to easy bleeding or bruising.
  • Autoimmune hemolytic anemia occurs when a person's immune system attacks their red blood cells, causing unusual tiredness, pale skin, and a fast heartbeat.
  • Heart valve abnormalities may occur, including valve thickening and valve nodules (masses of antibodies and clot-like clumps)
  • Other neurological symptoms like headache, seizures, vision changes, and cognitive problems may be seen.
  • Other skin manifestations like ulcers (open sores) and splinter hemorrhages (red or black streaks under a fingernail or toenail) can occur.

Pregnancy-Related Problems

Pregnancy-related complications may occur in antiphospholipid syndrome, including recurrent early miscarriage and fetal loss after 10 weeks gestation.

Late pregnancy complications like premature birth or fetal growth restriction associated with decreased blood flow to the fetus may also occur. The decreased blood flow is usually due to:

  • Preeclampsia is the new onset of high blood pressure, usually in the second half of pregnancy.
  • Placental insufficiency is impaired blood flow to the placenta resulting in a reduction in a decline in the delivery of nutrients and oxygen to the developing fetus.

Is a Successful Pregnancy Possible With APS?

Yes. Treatment of APS in pregnancy has improved outcomes to achieve successful live birth in more than 70% of pregnancies.

Catastrophic Antiphospholipid Syndrome

Antiphospholipid syndrome affects around 1% to 5% of the population, and catastrophic APS—the most devastating form of the disease—affects less than 1% of those individuals.

In catastrophic APS, several blood clots develop in small, medium, and large blood vessels throughout the body quickly. Extensive and rapid blood-clotting can lead to the failure of organs, namely the lungs, kidneys, brain, skin, and heart.

It's unclear exactly how catastrophic APS develops. Similar to typical APS, experts suspect to a trigger like an infection in genetically vulnerable individuals.

Survival With APS

While catastrophic APS has a mortality (death) rate of 50%, most people with APS live normal, healthy lives. In a European study that followed 1,000 people with APS, the survival probability (chance of living) at 10 years follow-up was nearly 91%.

Treatment to Manage Antiphospholipid Syndrome

A diagnosis of antiphospholipid syndrome requires the presence of symptoms consistent with APS (e.g., blood clot and/or pregnancy complication) and one or more persistently positive APS antibodies. "Persistently positive" means that at least one of the APS antibodies is present on a blood test taken at two separate times at least three months apart.

Once diagnosed with APS, anticoagulation is the mainstay of treatment. Also known as blood thinners, anticoagulants prevent existing blood clots from getting bigger and new blood clots from forming. 

Anticoagulants used to treat blood clots in APS are:

  • Heparin is given as an injection underneath the skin or intravenously (through a vein).
  • Low molecular weight heparin (LMWH) is given as an injection underneath the skin. Types of LMWH are Lovenox (enoxaparin), Fragmin (dalteparin), and Innohep (tinzaparin).
  • Jantoven or Coumadin (warfarin) is a pill used for the long-term treatment of blood clots. Warfarin requires monitoring with periodic blood tests.

In pregnancy, low-dose aspirin and/or LMWH may be used to prevent blood clots, miscarriage, or late pregnancy-related complications like preeclampsia and placental insufficiency.

Aspirin is not an anticoagulant but rather an antiplatelet drug that helps prevent blood clots by preventing platelets from clumping together.

Warfarin is avoided in pregnancy when possible. It may be restarted soon after delivery and is generally considered safe to take while breastfeeding.

APS Treatment Is Not Always Recommended

Individuals with antiphospholipid antibodies but no history of blood clots or pregnancy-related complications (if applicable) may not require any treatment.

Lifestyle Changes With Antiphospholipid Syndrome

Various lifestyle practices can help reduce the risk of blood clot formation.

Such practices include:

Keep in mind too that if taking warfarin, you must undergo regular international normalized ratio (INR) blood tests.

Based on the INR level, your warfarin dose may be adjusted. An INR above the target range carries an increased risk of bleeding, and an INR below the target range carries an increased risk of clotting.

Also, it's essential to maintain a stable intake of vitamin K when taking warfarin, as warfarin blocks a step in the blood-clotting process that depends on vitamin K. Consuming significantly lower or higher amounts of vitamin K can alter the INR, making you more prone to bleeding or clotting, respectively.

What Foods Are High in Vitamin K?

Examples of foods high in vitamin K include kale, spinach, Brussels sprouts, collard greens, sushi, broccoli, and green tea.

Other medications, herbs, or dietary products like alcohol, cannabis, Ginkgo biloba, ginger, and Saint-John's-wort can also interfere with warfarin's effect.

Speak with a healthcare provider before engaging in new dietary habits or taking a new prescription, recreational, or over-the-counter drug, vitamin, or supplement to avoid harmful interactions.

Summary

Antiphospholipid syndrome, or APS, is an autoimmune disease (when your immune system attacks its own tissue) associated with one of three APS antibodies, blood clots, and/or pregnancy-related complications, like recurrent miscarriages.

APS may occur on its own or with another autoimmune disease, namely lupus. While APS cannot be cured, it can be managed well in most cases with blood thinners, such as heparin, warfarin, or aspirin, depending on symptoms and the clinical scenario.

18 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018;4:17103. doi:10.1038/nrdp.2017.103

  2. Torres García J, Durán Agüero S. Fosfolípidos: propiedades y efectos sobre la salud [Phospholipids: properties and health effects]. Nutr Hosp. 2014;31(1):76-83. doi:10.3305/nh.2015.31.1.7961

  3. Mezhov V, Segan JD, Tran H, Cicuttini FM. Antiphospholipid syndrome: a clinical review. Med J Aust. 2019;211(4):184-188. doi:10.5694/mja2.50262

  4. Lambroussis CG, Foster D, Sharma A. Antiphospholipid syndrome secondary to lupus anticoagulant: case report for clinical anticoagulation determination. Cureus. 2022;14(8):e27702. doi:10.7759/cureus.27702

  5. Shah R, Mohammed YN, Koehler TJ, et al. Antiphospholipid antibodies and vitamin D deficiency in COVID-19 infection with and without venous or arterial thrombosis: A pilot case-control study. PLoS One. 2022 Jul 14;17(7):e0269466. doi:10.1371/journal.pone.0269466

  6. D'Angelo C, Franch O, Fernández-Paredes L, et al. Antiphospholipid antibodies overlapping in isolated neurological syndrome and multiple sclerosis: neurobiological insights and diagnostic challenges. Front Cell Neurosci. 2019;13:107. doi:10.3389/fncel.2019.00107

  7. National Organization for Rare Disorders. Antiphospholipid syndrome.

  8. de Azevedo FVA, Maia DG, de Carvalho JF, Rodrigues CEM. Renal involvement in antiphospholipid syndrome. Rheumatol Int. 2018;38(10):1777-1789. doi:10.1007/s00296-018-4040-2

  9. Tomasello R, Giordano G, Romano F, et al. Immune thrombocytopenia in antiphospholipid syndrome: is it primary or secondary? Biomedicines. 2021;9(9):1170. doi:10.3390/biomedicines9091170

  10. Bernardoff I, Picq A, Loiseau P, et al. Antiphospholipid antibodies and the risk of autoimmune hemolytic anemia in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2022;21(1):102913. doi:10.1016/j.autrev.2021.102913

  11. Kolitz T, Shiber S, Sharabi I, Winder A, Zandman-Goddard G. Cardiac manifestations of antiphospholipid syndrome with focus on its primary form. Front Immunol. 2019;10:941. doi:10.3389/fimmu.2019.00941

  12. Ricarte IF, Dutra LA, Abrantes FF, et al. Neurologic manifestations of antiphospholipid syndrome. Lupus. 2018 Aug;27(9):1404-1414. doi:10.1177/0961203318776110

  13. Dupré A, Morel N, Yelnik C, et al. Cutaneous Involvement in Catastrophic Antiphospholipid Syndrome in a Multicenter Cohort of 65 Patients. JAMA Dermatol. 2023 Jan 1;159(1):62-67. doi: 10.1001/jamadermatol.2022.5221

  14. Petri M. Improvements in diagnosis and risk assessment of primary and secondary antiphospholipid syndrome. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):415-420. doi:10.1182/hematology.2019000046

  15. Cervera R, Serrano R, Pons-Estel GJ, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2015;74(6):1011-1018. doi:10.1136/annrheumdis-2013-204838

  16. Tektonidou MG, Andreoli L, Limper M, Tincani A, Ward MM. Management of thrombotic and obstetric antiphospholipid syndrome: a systematic literature review informing the EULAR recommendations for the management of antiphospholipid syndrome in adults. RMD Open. 2019 Apr 28;5(1):e000924. doi:10.1136/rmdopen-2019-000924

  17. Lee EE, Jun JK, Lee EB. Management of women with antiphospholipid antibodies or antiphospholipid syndrome during pregnancy. J Korean Med Sci. 2021;36(4):e24. doi:10.3346/jkms.2021.36.e24

  18. Tan CSS, Lee SWH. Warfarin and food, herbal or dietary supplement interactions: a systematic review. Br J Clin Pharmacol. 2021;87(2):352-374. doi:10.1111/bcp.14404

Colleen Doherty, MD

By Colleen Doherty, MD
Dr. Doherty is a board-certified internist and writer living with multiple sclerosis. She is based in Chicago.